The Role of an Aggrecan 32mer Fragment in Post-Traumatic Osteoarthritis
Abstract
Recommended to be brief (approx. 200 words) of the main findings during the reporting period. In this second reporting period, we achieved three major milestones: 1. We finalized the histological analysis of all knees of the prophylactic experiment performed in year 1. We found no effect of a 10-week prophylactic treatment with AF 28 on cartilage damage or proteoglycan loss. Analyses of bone damage are in progress. 2. We completed a 16-week experiment where mice were treated starting 2 weeks after DMM surgery. This treatment strategy had no effect on pain-related behaviors. 3. We successfully developed an assay to measure the 32-mer fragment in human serum, which has great potential as a novel biomarker for OA/OA pain, as well as a target marker for aggrecanase activity. Unfortunately, we have also encountered issues that delayed progress and will require substantive changes going forward: 1. The data collected to date suggest that AF-28 is not a neutralizing antibody. Further in vivo experiments are on hold until analysis of the first DMM experiment is complete. 2. PI Fosang has a health issue and we therefore, urgently requested that co-I Malfait can share the role of Co-PI.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2018
- Accession Number
- AD1094324
Entities
People
- Amanda Fosang
- Anne-marie Malfait
Organizations
- University of Melbourne